Page 6 - QR-SLE-8_5_24
P. 6

QUICK REFERENCE FOR HEALTHCARE PROVIDERS  MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS  QUICK REFERENCE FOR HEALTHCARE PROVIDERS  MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
                           TREATMENT                                                 CLINICAL MANIFESTATIONS
      •  Principles of SLE treatment are to achieve:                                                   Neuropsychiatry
         disease remission                                                                       • Polyneuropathy   •  Acute confusion state
         disease flare prevention                                                                • Cerebrovascular  • Headache/Migraine
         organ damage prevention                                                                   disease/Stroke   •  Transverse myelitis
                                                                                                             •  Cognitive impairment
                                                                                                  • Seizure
         quality of life improvement                                                             • Psychosis
         minimisation of drug side-effects                          Mucocutaneous
                                                                     •  Malar rash
      •  If complete remission cannot be achieved, the lowest possible   •  Oral ulcers                    Eye
       disease activity in all organs involved should be targeted.   • Photosensitivity                    •  Dry eyes
                                                                     •  Discoid rash                       •  Retinal vasculitis
                                                                     • Alopecia                            •  Optic neuritis
           FREQUENCY & PARAMETERS FOR MONITORING                   Cardio-respiratory
                                                                   • ILD                                      Haematology
                                Patients with                      • Pericarditis                             • Leukopenia
                               active disease  Patients with stable/  • PAH                                   • Thrombocytopenia
                        At first            low disease activity   • Pleurisy                                 • AIHA
     Assessments              should be reviewed
                         visit               should be reviewed    • Serositis                                • Lymphopenia
                                at least every  every 6 - 12 months  • Myocarditis                            • APS
                                1 - 3 months                       • Libman-Sacks
      Clinical                                                       endocarditis
      History                                                        Renal                                    Gastrointestinal
      Vital signs                                                    • Proteinuria                            • Pancreatitis
      Clinical examination                                           • Microscopic                            • Enteritis
      Drug review                                                      haematuria                             •  Lupoid hepatitis
      Blood tests
      FBC                                                                                                   • Raynaud’s
      RP                                                                Vasculitis                            phenomenon
      LFT
      CRP                             a              a
      ESR                                                                                                Musculoskeletal
                                                                                                         • Arthritis/Arthralgia
      Bone profile         a          a              a                   Constitutional                  • Myositis
      Vitamin D3           a        -                a                   symptoms
                                                                         • Fever
      Immunology/serology                                                • Fatigue
      ANA                           -               -                    •  Weight loss
      Anti-dsDNA                      a              a
      C3/C4 levels                    a              a
      aPL                             a              a,p
      ENA                             a              a,p
      Immunoglobulin A, G, M  a       a              a             AIHA = autoimmune haemolytic anaemia; APS  = antiphospholipid syndrome; ILD =
      Direct Coombs’ test             a              a             interstitial lung disease; PAH = pulmonary arterial hypertension
      Urine
      UFEME
      Urine random protein:
      creatinine ratio OR   a         a              a
      24-hour urine protein
       =  indicated;     =  when indicated;     =  when indicated during pregnancy; -  =  not
                              a,p
                a
     indicated; anti-dsDNA = anti-double stranded deoxyribonucleic acid; ENA = extractable
     nuclear antigen
                                5                                                            2
   1   2   3   4   5   6   7   8